

Stock Sentiment Analysis Report

Natera (NTRA)

Analysis Period: 2026-03-24 to 2026-04-23 (30 days)

Generated: 2026-04-23 10:09:52

Executive Summary


Sentiment analysis for Natera (NTRA) from 2026-03-24 to 2026-04-23. Analyzed 109 items across FDA and news sources.

Sentiment Breakdown

| Category | Count | Percentage |
|--------------|------------|---------------|
| Positive | 40 | 36.7% |
| Negative | 33 | 30.3% |
| Neutral | 36 | 33.0% |
| Total | 109 | 100.0% |

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

| Title | Source | Date | Score |
|---|---------------|------------|-------|
| Single Cell Sequencing Market Outlook Report 2026-... | news | 2026-04-20 | 0.941 |
| 20 Abstracts at AACR Highlight Scale, Innovation a... | alpha_vantage | 2026-04-08 | 0.812 |
| 20 Abstracts at AACR Highlight Scale, Innovation a... | alpha_vantage | 2026-04-07 | 0.812 |
| Kura Oncology Reports Darlifarnib Plus Cabozantini... | news | 2026-04-17 | 0.772 |
| Natera Inc stock (US6323071042): Is cell-free DNA ... | alpha_vantage | 2026-04-14 | 0.710 |

Top Negative Events

| Title | Source | Date | Score |
|---|--------|------------|--------|
| Colorectal Cancer Advocates Urge Congress to Fund ... | news | 2026-03-27 | -0.945 |
| Peripheral blood transcriptional profiling predict... | pubmed | 2026 Apr 2 | -0.791 |
| ASO Author Reflections: Potential of Circulating T... | pubmed | 2026 Apr 1 | -0.791 |
| Colorectal Cancer and Mortality Risk Among Older A... | pubmed | 2026 Apr 9 | -0.758 |
| Therapeutic vulnerabilities exposed by the 9p21 lo... | pubmed | 2026 Apr 1 | -0.694 |